RxDoctor Payments Data

Edgar Agvanyan, MD

Family Medicine · Glendale, CANPI 1225288582

Payments from drug & device makers

$2,047in general payments, 2019–2025

Across 115 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$380
  • Novo Nordisk$244
  • Mannkind Corporation$241
  • AbbVie$153
  • Sanofi-aventis U.S. LLC$148
  • Merck$135
  • plus $747 from 17 others

What the payments were for

  • Food & beverage$2,02899%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,047 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$42,229
Medicare patients
136
Services billed
407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin81$64,180
JanuviaSitagliptin Phosphate48$41,262
EliquisApixaban47$38,295
OzempicSemaglutide33$30,748
EntrestoSacubitril/Valsartan28$22,983
MounjaroTirzepatide20$21,444
LinzessLinaclotide36$21,368
TradjentaLinagliptin34$16,461
JanumetSitagliptin Phos/Metformin Hcl16$11,962
Diclofenac Sodium59$10,033
RybelsusSemaglutide11$9,703
VascepaIcosapent Ethyl19$8,061
Breo ElliptaFluticasone/Vilanterol20$7,330
DapagliflozinDapagliflozin Propanediol11$7,044
Combivent RespimatIpratropium/Albuterol Sulfate13$6,000

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat$128$92,567139 claims
MerckJanuvia, Janumet$135$53,22464 claims
Novo NordiskOzempic, Rybelsus$244$40,45144 claims
PfizerEliquis$28$38,29547 claims
Lilly USA, LLCMounjaro$88$21,44420 claims
AbbVieLinzess$153$21,36836 claims
GSKBreo Ellipta$29$7,33020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →